North America Kidney Cancer Therapeutics & Diagnostics Market - Segmented by type of cancer and geography (2015-2020)
The frequency of kidney cancer, worldwide, has increased in the recent years. Changes in lifestyle, excessive smoking, increased consumption of alcohol and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Renal cell carcinoma (RCC), also known as renal cell cancer or renal cell adenocarcinoma, is the most common type of kidney cancer. About 9 out of 10 kidney cancers are renal cell carcinomas.
The Kidney Cancer Market is expected to grow modestly from USD 1,018 million in 2015, at a CAGR of XX%.
The North America kidney cancer therapeutics & diagnostic market is segmented based on:
Renal cell carcinoma
Transitional Cell Cancer
Other rare types
CT Scan an
In addition, the revenue generated by major drugs like Afinitor, Avastin, Inlyta, Nexavar, Proleukin, Votrient and Sutent in the market is also discussed.
North America region has the largest share in the global kidney cancer drugs market. Rising number of kidney cancer cases and other kidney diseases is the major element driving the growth in this region.
Some of the key participants in the industry include Pfizer, GlaxoSmithKline, Sanofi S.A, Roche, Novartis, Bayer, Abbott Laboratories, Genentech etc.
Increasing kidney cancer cases
Drug innovations with regard to the kidney cancer
Rise in aging populace
Advanced health care
Upsurge in awareness about kidney diseases and their existing therapies in the market
Increasing health care expenditure
Rise in number of patent expirations
Rise in use of generic drugs
Low success rate in clinical trials
PDF E-mail From Publisher
Multi User License (2-5 Users) Fulfilled by Publisher